Preparation and in vitro/in vivo characterization of porous sublingual tablets containing ternary kneaded solid system of Vinpocetine with β-Cyclodextrin and Hydroxy Acid

Scientia Pharmaceutica

Volumn 78, Issue 2, 2010, Pages 363-379

  Aburahma, Mona H ^a   El Laithy, Hanan M ^a   Hamza, Yassin El Said ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

cyclodextrin; Hydroxy acids; Sublimable materials; Sublingual porous tablets; Vinpocetine

Indexed keywords

BETA CYCLODEXTRIN; CAMPHOR; CITRIC ACID; MENTHOL; MW 1135; TARTARIC ACID; UNCLASSIFIED DRUG; VINPOCETINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RABBIT; TABLET COMPRESSION; TABLET FORMULATION; TABLET POROSITY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77954634712     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0912-04     Document Type: Article

References (34)

1. Chen J, Cai J, Tao W, Mei N, Cao S, Jiang XG. Determination of apovincaminic acid in human plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detection. J Chromatogr B. 2006; 830: 201-206. doi:10.1016/j.jchromb.2005.10.052
2. Szakács T, Veres Z, Vereczkey L. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Pol J Pharmacol. 2001; 53: 623-628. doi:10.1002/jps.2600810102
3. Kata M, Lukács M. Enhancement of solubility of vinpocetine base with γ-cyclodextrin. Pharmazie. 1986; 41: 151-152. PMid:3725857
4. Grandt R, Beitinger R, Schaltenbrand R, Braun W. Vinpocetine pharmacokinetics in elderly subjects. Arzneimittelforschung. 1989; 39: 1599-1602. PMid:2624613
5. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992; 81: 1-10. doi:10.1002/jps.2600810102
6. Fridriksdottir H, Loftsson T, Gudmunsson JA, Bjarnason GJ, Kjeld M. Design and in vivo testing of 17 β-esradiol-HP CD sublingual tablets. Pharmazie. 1996; 51: 39-42. PMid:8999433
7. Hua L, Weisan P, Jiayu L, Ying Z. Preparation, evaluation, and NMR characterization of vinpocetine microemulsion for transdermal delivery. Drug Dev Ind Pharm. 2004; 30: 657-666. doi:10.1081/DDC-120039183
8. Mannila J, Järvinen T, Järvinen K, Tarvainen M, Jarho P. Effects of RM-β-CD on sublingual bioavailability of Δ9-tetrahydrocannabinol in rabbits. Eur J Pharm Sci. 2005; 26: 71-77. doi:10.1016/j.ejps.2005.04.020
9. Mannila J, Järvinen T, Järvinen K, Tarvainen M, Jarho P. Sublingual administration of Δ9-tetrahydrocannabinol/ β-cyclodextrin complex increases the bioavailability of Δ9-tetrahydrocannabinol in rabbits. Life Sci. 2006; 78: 1911-1914. doi:10.1016/j.lfs.2005.08.025
10. Szejtli J, Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur J Pharm Biopharm. 2005; 61: 115-125. doi:10.1016/j.ejpb.2005.05.006
11. Fenyvesi E, Vikmon M, Szeman J, Redenti E, Delcanale M, Ventura P, Szejtli J. Interaction of hydroxy acids with β-cyclodextrin. J Incl Phenom. 1999; 33: 339-344. doi:10.1023/A:1008094702632
12. Mura P, Faucci M T, Manderioli A, Bramanti G. Multicomponent systems of econazole with hydroxyacids and cyclodextrins. J Incl Phenom. 2001; 39: 131-138. doi:10.1023/A:1008114411503
13. Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M, Nyström C. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm. 2003; 20; 327-334. doi:10.1016/j.ejps.2003.07.002
14. Koizumi K, Watanabe Y, Morita K, Utoguchi N, Matsumoto M. New method of preparing high porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm. 1997; 152: 127-131. doi:10.1016/S0378-5173(97)04924-7
15. Gohel M, Patel M, Amin A, Agrawal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004; 10-15. doi:10.1208/pt050336
16. Aly M, Laith A, Hatem A. Licorice: A possible anti-inflamatory and anti-ulcer drug. AAPS PharmSciTech. 2005; 6: E74-E82. doi:10.1208/pt060113
17. Ribeiroa L, Ferreirab DC, Veiga FJB. In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. J Control Rel. 2005; 103: 325-339. doi:10.1016/j.jconrel.2004.12.001
18. Hamza YE, Aburahma MH Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: Utility of cyclodextrin and xanthan gum combination. AAPS PharmSciTech. 2009; 10: 1357-1367. doi:10.1208/s12249-009-9336-9
19. Fernandes CM, Teresa VM, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins nclusion compounds. Eur J Pharm Sci. 2002; 15: 79-88. doi:10.1016/S0928-0987(01)00208-1
20. Baboota S, Agarwal SP. Preparation and characterisation of meloxicam hydroxy propyl β-cyclodextrin inclusion complex. J Incl Phenom. 2005; 51: 219-224. doi:10.1007/s10847-004-6957-1
21. Barillaro V, Bertholet P, Sandrine H. Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide. J Pharm Pharm Sci. 2004; 7: 378-388. PMid:15576020
22. Munoz A, Ndou TT, Zung JB, Greene KL, Live DH. Influence of Alcohols on the β Cyclodextrin/Acridine Complex. J Am Chem Soc. 1993; 115: 292-298. doi:10.1021/ja00054a042
23. Kuno Y, Kojima, M, Ando S, Nakagami H. Evaluating of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Control Rel. 2005; 105: 16-22. doi:10.1016/j.jconrel.2005.01.018
24. Zhao N, Augsburger LL. The influence of swelling capacity of superdisintegrants in different pH media on the dissolution of hydrochlorothiazide from directly compressed tablets. AAPS PharmSciTech. 2005; 6: E120-E126. doi:10.1208/pt060119
25. Bredenberg S, Nyström C. In vitro evaluation of bioadhesion in particulate systems and possible improvement using interactive mixtures. J Pharm Pharmacol. 2003; 55: 169-177. doi:10.1211/002235702423
26. Shangraw R, Mitrevej A, Shah M. A new era of tablet disintegrants. Pharm Technol. 1980; 4: 49-57.
27. The British Pharmacopoeia, British Pharmacopoeia Commission, HMSO, London, 2007 (Electronic version).
28. Bi YX, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm. 1999; 25: 571-581. doi:10.1081/DDC-100102211
29. Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Del. 2005; 2: 335-351. doi:10.1517/17425247.2.1.335
30. Nogami H, Nagai T, Yotsuyanagi I. Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chem Pharm Bull. 1969;17: 499-509.
31. Khan A. The concept of dissolution efficiency. J Pharm Pharmacol. 1975; 27: 48- 49. PMid:235616
32. Ito A, Sugihara M. Development of oral dosage forms for elderly patients: use of agar as base of rapidly disintegrating oral tablets. Chem Pharm Bull. 1996; 44: 2132-2136.
33. Odou P, Barthelemy C, Chatelier D, Luyckx M, Brunet C, Dine T, Gressier B, Cazin M, Cazin JC, Robert H. Pharmacokinetics of midazolam: comparison of sublingual and intravenous routes in rabbit. Eur J Drug Metab Pharmacokinet. 1999; 24: 1-7. PMid:10412885
34. Abd Elbary A, Foda N, El-Gazayerly O, El Khatib M. Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. Anal Lett. 2002; 35: 1041-1054. doi:10.1081/AL-120004554